Real-World Efficacy of MOUD and Psychotherapy for Opioid Use Disorder

Overview

This large retrospective cohort study of 18,047 adults with opioid dependence found that both medication for opioid use disorder (MOUD) and psychotherapy independently increased remission rates compared to no treatment. The combination of buprenorphine and psychotherapy showed the strongest association with remission, highlighting the additive benefit of integrated treatment approaches.

Background

Opioid use disorder (OUD) is a chronic, relapsing condition with significant mortality and social burden in the United States. Evidence-based treatments include FDA-approved medications such as methadone and buprenorphine, which reduce withdrawal and craving, and psychosocial therapies that address behavioral and environmental factors. Despite proven efficacy, access to MOUD and sustained behavioral therapy remains limited, and real-world comparative effectiveness data at a national scale are scarce.

Data Highlights

Key Findings

• Both buprenorphine and methadone independently doubled the likelihood of remission compared to no treatment.
• Psychotherapy alone, even at shorter session durations (30–45 minutes), was significantly associated with higher remission rates.
• The combination of buprenorphine and psychotherapy demonstrated the strongest effect, more than doubling remission likelihood compared to either treatment alone.
• Co-occurring anxiety diagnoses and gabapentinoid prescriptions were positively associated with remission outcomes.
• Benzodiazepine co-prescription was negatively associated with remission, indicating potential harm.
• This study leveraged a large, diverse, national multi-healthcare organization database, enhancing generalizability of findings.

Clinical Implications

Clinicians should consider integrating both pharmacologic and psychosocial interventions to optimize remission outcomes in patients with OUD. The additive benefit of combining MOUD, particularly buprenorphine, with structured psychotherapy supports policies and clinical practices that promote comprehensive, multimodal harm-reduction strategies. Caution is warranted with benzodiazepine co-prescribing due to its negative association with remission.

Conclusion

This national-scale analysis confirms that both MOUD and psychotherapy independently improve remission in opioid dependence, with combined treatment yielding the greatest benefit. Embedding integrated harm-reduction services within routine care is essential to enhance recovery outcomes.

References

1. Study Authors/2025 -- Comparative Analysis of Real-World Efficacy of Medication-Assisted Treatment and Psychotherapy for Opioid Use Disorder